[Mortality trends in gynecologic tumors in Soria. 1950-1985]. / Tendencias de mortalidad por tumores ginecológicos en Soria. 1950-1985.

We have carried out in the province of Soria neoplastic mortality tendency curves for tumors in the breast, uterus and ovaries, on the basis of their adjusted rates of mortality during four periods: three decades (1950-59/60-69/70-79) and one six-year period (1980-85). We have observed an increased risk of mortality due to breast tumors in women, which is statistically significant (p less than 0.01) in the global provincial figure, which has gone from an adjusted rate of 6.08 deaths per 10(5) women in 1950-59 to 14.25 in the years 1980-85. We have also detected an increased risk of ovarian tumors in the provincial total, rising from 0.48 to 2.0 deaths per 10(5) women, while those located in the uterus show a virtually stable mortality over the 36 years under study (5.89/1950-59) (5.24/1980-85) x 10(5) women. In relation to other existing figures, our rates are, in the case of breast and ovarian tumors, similar to the global Spanish figures and lower than those for Cataluña and Navarra. In the case of tumors of the uterus, the adjusted mortality rates are lower than the national average and lower than any other Spanish figures available.

[Histopathologic evaluation of death certificates in Soria in 1985]. / Valoración histopatológica de los boletines de defunción en Soria en 1985.

The aim of this paper is to evaluate the quality of the Death Certificates by means of the Death Statistics Bulletins, in their NEOPLASIC aspect in the year 1985 in the Province of Soria, determining the histopathologic confirmation of the deaths by means of the neoplasic patients' records in the two existing Pathology Services. An overall histologic verification of 80.76% is observed in the cases with an I.C. of +/- 4.79. In the case of BREAST, HEMATOLOGIC, OROPHARYNX, ENDOMETRIUM, ESOPHAGUS, OVARIAN, LARYNX and VULVA tumors, it is 100%. Whereas it is 14.3% in HEPATIC Tumors. Of the total of deaths registered in said year, the percentage of deaths caused by malignant neoplasias is over 26%, more than a fourth of which were Gastric. The preparation of the Death Certificates should be modified so that they can be objectively evaluated epidemiologically without bias or mistakes.

[Trends in urologic neoplasm mortality and incidence (prostate, bladder, and kidney). Soria, 1950-1988]. / Tendencias de mortalidad e incidencia neoplásica urológica (próstata, vejiga y riñón). Soria 1950-1988.

The mortality rate for urological tumors in the province of Soria, Spain, was recorded from 1950 to 1988, as well as its incidence for the period 1981-1988. We classified data according to sex, age groups, tumor site and type, and patient residence (urban/rural). Rates were adjusted for the foregoing parameters and decades (1950-1959, 1960-1969, 1970-1979, 1980-1988) and compared with those of other national and international registries. Prostate, bladder and kidney tumors in men showed an increased mortality rate for the period 1950-1988 which was statistically significant (p less than 0.01), whereas the female mortality rate for this period hardly changed and remained very low. A higher risk potential was observed for bladder tumors for the urban than for the rural areas, with a significant difference for mortality and incidence for both sexes (p less than 0.01). There was also a higher incidence for tumors of the prostate in the urban areas (p less than 0.01). Like most registries, there was a prevalence of bladder tumors in males, in both areas, in mortality and incidence (p less than 0.01). Comparison with other national registries show our mortality and incidence rates are lower for both sexes. Comparison with international registries show this province has a medium-low risk for prostatic tumors and medium risk for bladder tumors in males and females. The risk potential for renal tumors could not be compared objectively. The incidence/mortality ratio (I/M) (adjusted rates) shows prognosis is good for bladder tumors (better in women than in men), poor for prostatic tumors, and bad for renal tumors.